A discounted cash flow analysis suggests shares of the Malaysian poultry and seafood firm may be overvalued at current levels, raising questions for investors.
Texas Instruments (TXN) reported a 70% year-over-year surge in data center orders, prompting the company to break out the segment separately. Management forecasts the first sequential revenue growth since 2008, citing improving industrial trends and AI-related infrastructure spending.
As Diebold Nixdorf accelerates its AI-driven self-checkout initiatives, highlighted by a new study on the Australian retail market, investors are weighing whether this technological pivot can solidify its ongoing operational turnaround and justify its current valuation.
Oracle Corp. plans a colossal $45-$50 billion capital raise in 2026 to expand its cloud infrastructure, aiming to meet surging demand from AI giants like OpenAI and Nvidia. The move comes as the company's aggressive data center spending pushes its free cash flow negative, a condition projected to last for years.
Micron Technology, a key player in memory chips, is poised for explosive earnings growth fueled by insatiable AI demand. Yet, its cyclical nature and commoditized market pose significant long-term risks for investors.
The 179-year-old tobacco giant Philip Morris International is closing its Richmond, Virginia office, eliminating 135 positions, as it aggressively restructures around its smoke-free product portfolio, led by the ZYN nicotine pouch brand.
After a relatively subdued 2025, Wall Street's projections for Nvidia's revenue growth remain robust. Analysts are debating whether the chipmaker's current valuation sets the stage for a significant rebound or a period of consolidation.
Singapore's Venture Corporation (SGX:V03) has delivered a robust 38% total shareholder return over the past year, buoyed by dividends. However, a closer look reveals declining earnings and revenue, raising questions about the sustainability of its recent market favor and its longer-term trajectory.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
Broadcom secures a pivotal, multi-year agreement to supply custom AI chips to OpenAI, cementing its role as a key silicon partner for tech giants. However, the semiconductor leader must simultaneously navigate customer churn from its VMware unit and heightened regulatory scrutiny, presenting a complex risk-reward profile for investors.
With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.
An analysis of wealth accumulation among the world's top billionaires reveals staggering gains during the current presidential term, with policy and market dynamics fueling unprecedented fortunes.
While both ETFs target the high-flying U.S. technology sector, a closer look reveals critical distinctions in diversification, concentration risk, and liquidity that could sway long-term portfolio outcomes.
Beyond their legendary rivalry in the truck market, Ford and General Motors are delivering substantial value to shareholders through distinct but equally compelling financial strategies.
After years of sluggish sales and brand challenges, Starbucks is betting on a dual strategy: deploying AI to streamline operations while reinvesting in the in-store experience. CEO Brian Niccol outlines the plan he believes will restore growth and community connection.
Meta CEO Mark Zuckerberg's forecast of a major AI infrastructure build-out through 2026 suggests continued robust spending on Nvidia's hardware, reinforcing the chipmaker's central role in the ongoing tech boom.
Despite a stellar 38% gain over the past year, analysis suggests Federated Hermes (NYSE: FHI) shares may still be trading at a discount to their intrinsic value, presenting a potential opportunity in the capital markets sector.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
RH shares have slumped roughly 13% over the past week, contrasting sharply with strong gains over the prior month. This pullback places the luxury home furnishings retailer under a valuation microscope, with analysts debating whether the dip presents a buying opportunity or signals deeper challenges ahead.
Shares of Deckers Outdoor Corp. surged nearly 20% following a robust quarterly report and an optimistic fiscal 2026 outlook, driven by exceptional performance from its UGG and HOKA footwear brands.
